Entera Bio (NASDAQ:ENTX - Get Free Report) is expected to announce its earnings results before the market opens on Friday, March 14th. Analysts expect the company to announce earnings of ($0.08) per share and revenue of $0.04 million for the quarter.
NASDAQ:ENTX opened at $1.87 on Friday. The firm's 50 day simple moving average is $2.29 and its 200 day simple moving average is $2.00. Entera Bio has a one year low of $1.30 and a one year high of $3.35. The company has a market cap of $66.92 million, a PE ratio of -7.19 and a beta of 1.62.
Separately, HC Wainwright reiterated a "buy" rating and set a $10.00 target price on shares of Entera Bio in a research report on Monday, November 11th.
View Our Latest Stock Analysis on Entera Bio
Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Entera Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Entera Bio wasn't on the list.
While Entera Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.